Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 3/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291881 | 0.88 | CA14 (0.41) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL14709092 | 0.86 | CA14 (0.38) | KMT2ACA14L3MBTL1HDAC3HDAC1 | |
| SCHEMBL12917526 | 0.86 | CA14 (0.39) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL14708941 | 0.83 | CA14 (0.45) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL16141285 | 0.83 | CA14 (0.45) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL16330568 | 0.80 | HDAC3 (0.40) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL12917528 | 0.79 | KIF11 (0.46) | KIF11 | |
| SCHEMBL18291847 | 0.78 | CA14 (0.36) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL17493273 | 0.77 | CA14 (0.41) | CA14L3MBTL1HDAC3HDAC1HDAC2 | |
| SCHEMBL17080678 | 0.76 | MGLL (0.46) | CA14L3MBTL1ALDH1A1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2015-02-26 | — | — | US | disclosed |
| US-8906847-B2 | Prodrug comprising a drug linker conjugate | ASCENDIS PHARMA A/S (DK) | 2014-12-09 | — | — | US | disclosed |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057221-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | MEN1 1323/4885TSHR 991/4885KMT2A 327/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | MEN1 1323/4885TSHR 991/4885KMT2A 327/4885 |
| US-20110053848-A1 | PRODRUG COMPRISING A DRUG LINKER CONJUGATE | H1-0, H1-3, H1-2 | MEN1 1331/4885TSHR 997/4885KMT2A 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.